JPWO2021245055A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021245055A5 JPWO2021245055A5 JP2022574317A JP2022574317A JPWO2021245055A5 JP WO2021245055 A5 JPWO2021245055 A5 JP WO2021245055A5 JP 2022574317 A JP2022574317 A JP 2022574317A JP 2022574317 A JP2022574317 A JP 2022574317A JP WO2021245055 A5 JPWO2021245055 A5 JP WO2021245055A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- alkoxy
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 209
- 125000000623 heterocyclic group Chemical group 0.000 claims 46
- 229910052739 hydrogen Inorganic materials 0.000 claims 44
- 239000001257 hydrogen Substances 0.000 claims 44
- 229910052736 halogen Inorganic materials 0.000 claims 40
- 150000002367 halogens Chemical class 0.000 claims 40
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims 37
- 125000003545 alkoxy group Chemical group 0.000 claims 36
- 150000002431 hydrogen Chemical class 0.000 claims 34
- 229910052799 carbon Inorganic materials 0.000 claims 32
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 26
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 17
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims 4
- 125000005549 heteroarylene group Chemical group 0.000 claims 4
- -1 -OH Chemical group 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010073360 Appendix cancer Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000000062 kidney sarcoma Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 125000000466 oxiranyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033505P | 2020-06-02 | 2020-06-02 | |
| US63/033,505 | 2020-06-02 | ||
| EP20212067 | 2020-12-05 | ||
| EP20212067.1 | 2020-12-05 | ||
| PCT/EP2021/064616 WO2021245055A1 (en) | 2020-06-02 | 2021-06-01 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528623A JP2023528623A (ja) | 2023-07-05 |
| JPWO2021245055A5 true JPWO2021245055A5 (fi) | 2024-06-10 |
Family
ID=76269742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574134A Pending JP2023527891A (ja) | 2020-06-02 | 2021-06-01 | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
| JP2022574317A Pending JP2023528623A (ja) | 2020-06-02 | 2021-06-01 | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574134A Pending JP2023527891A (ja) | 2020-06-02 | 2021-06-01 | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11945812B2 (fi) |
| EP (2) | EP4157836A1 (fi) |
| JP (2) | JP2023527891A (fi) |
| KR (1) | KR20230019462A (fi) |
| CN (2) | CN116034106A (fi) |
| AU (1) | AU2021285032A1 (fi) |
| BR (1) | BR112022023462A2 (fi) |
| CA (1) | CA3183656A1 (fi) |
| CL (1) | CL2022003289A1 (fi) |
| CO (1) | CO2022017049A2 (fi) |
| CR (1) | CR20220614A (fi) |
| DO (1) | DOP2022000266A (fi) |
| EC (1) | ECSP22089077A (fi) |
| IL (1) | IL298633A (fi) |
| MX (1) | MX2022015260A (fi) |
| PE (1) | PE20240493A1 (fi) |
| TW (1) | TW202210474A (fi) |
| WO (2) | WO2021245051A1 (fi) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3790551A4 (en) | 2018-05-07 | 2022-03-09 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| CN115135315A (zh) | 2019-12-20 | 2022-09-30 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
| EP4157836A1 (en) | 2020-06-02 | 2023-04-05 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| AR125787A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
| TW202337432A (zh) * | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| CN118591540A (zh) * | 2021-12-01 | 2024-09-03 | 勃林格殷格翰国际有限公司 | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 |
| CN118574835A (zh) | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) * | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CA3240980A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118339153A (zh) * | 2021-12-22 | 2024-07-12 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的杂芳族化合物 |
| TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
| AU2023218370A1 (en) | 2022-02-09 | 2024-09-19 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2023244599A1 (en) * | 2022-06-15 | 2023-12-21 | Mirati Therapeutics, Inc. | Pan-kras inhibitors |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912400B (zh) * | 2004-06-11 | 2013-06-26 | 日本烟草产业株式会社 | 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物 |
| UY32317A (es) | 2008-12-12 | 2010-07-30 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| WO2013136254A1 (en) | 2012-03-14 | 2013-09-19 | Lupin Limited | Heterocyclyl compounds |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP3055290B1 (en) * | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JP6577958B2 (ja) | 2014-04-11 | 2019-09-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用 |
| JP6503386B2 (ja) | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| ES2739697T3 (es) | 2014-08-21 | 2020-02-03 | Boehringer Ingelheim Int | Nuevos compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53 |
| CA3000063A1 (en) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| JP7039489B2 (ja) * | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| BR112019011044A2 (pt) * | 2016-11-30 | 2019-10-08 | Bantam Pharmaceutical Llc | compostos pirazol substituídos e métodos de uso no tratamento de doenças hiperproliferativas |
| HUE056777T2 (hu) | 2016-12-22 | 2022-03-28 | Amgen Inc | Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére |
| US10898487B2 (en) | 2016-12-22 | 2021-01-26 | Boehringer Ingelheim International Gmbh | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CA3056970A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AU2018369759B2 (en) | 2017-11-15 | 2022-11-24 | Array Biopharma Inc. | KRas G12C inhibitors |
| SG11202005881YA (en) | 2017-12-21 | 2020-07-29 | Boehringer Ingelheim Int | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| EP3781565A1 (en) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| AU2019312670A1 (en) * | 2018-08-01 | 2021-02-04 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP2022522778A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロシクリル化合物及びその使用 |
| WO2020177629A1 (zh) | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| WO2020236940A1 (en) | 2019-05-20 | 2020-11-26 | California Institute Of Technology | Kras g12c inhibitors and uses thereof |
| AU2020402701B2 (en) | 2019-12-11 | 2024-03-14 | Eli Lilly And Company | KRas G12C inhibitors |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| TWI770760B (zh) | 2020-01-08 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 螺環四氫喹唑啉 |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| CN113683616A (zh) | 2020-05-18 | 2021-11-23 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
| EP4157836A1 (en) | 2020-06-02 | 2023-04-05 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4441054A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20230227470A1 (en) | 2021-12-01 | 2023-07-20 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118591540A (zh) | 2021-12-01 | 2024-09-03 | 勃林格殷格翰国际有限公司 | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 |
| TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118574835A (zh) | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
-
2021
- 2021-06-01 EP EP21729875.1A patent/EP4157836A1/en active Pending
- 2021-06-01 TW TW110119842A patent/TW202210474A/zh unknown
- 2021-06-01 MX MX2022015260A patent/MX2022015260A/es unknown
- 2021-06-01 KR KR1020227046273A patent/KR20230019462A/ko active Search and Examination
- 2021-06-01 CA CA3183656A patent/CA3183656A1/en active Pending
- 2021-06-01 US US17/335,620 patent/US11945812B2/en active Active
- 2021-06-01 PE PE2022002820A patent/PE20240493A1/es unknown
- 2021-06-01 WO PCT/EP2021/064612 patent/WO2021245051A1/en active Application Filing
- 2021-06-01 CN CN202180039453.3A patent/CN116034106A/zh active Pending
- 2021-06-01 BR BR112022023462A patent/BR112022023462A2/pt unknown
- 2021-06-01 JP JP2022574134A patent/JP2023527891A/ja active Pending
- 2021-06-01 US US18/000,442 patent/US20230212164A1/en active Pending
- 2021-06-01 CR CR20220614A patent/CR20220614A/es unknown
- 2021-06-01 AU AU2021285032A patent/AU2021285032A1/en active Pending
- 2021-06-01 CN CN202180059643.1A patent/CN116234806A/zh active Pending
- 2021-06-01 WO PCT/EP2021/064616 patent/WO2021245055A1/en unknown
- 2021-06-01 JP JP2022574317A patent/JP2023528623A/ja active Pending
- 2021-06-01 EP EP21729877.7A patent/EP4157837A1/en active Pending
- 2021-06-01 IL IL298633A patent/IL298633A/en unknown
-
2022
- 2022-11-21 EC ECSENADI202289077A patent/ECSP22089077A/es unknown
- 2022-11-23 CL CL2022003289A patent/CL2022003289A1/es unknown
- 2022-11-25 DO DO2022000266A patent/DOP2022000266A/es unknown
- 2022-11-29 CO CONC2022/0017049A patent/CO2022017049A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021245055A5 (fi) | ||
| JPWO2021245051A5 (fi) | ||
| JP2020517616A5 (fi) | ||
| JP2014500870A5 (fi) | ||
| JP2019517487A5 (fi) | ||
| JP2019513778A5 (fi) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2016505586A5 (fi) | ||
| JP2019131579A5 (fi) | ||
| JP2012523457A5 (fi) | ||
| CA2579915A1 (en) | Indole derivatives and their use as inhibitors of p53-mdm2 interaction | |
| JP2015510886A5 (fi) | ||
| JP2009535307A5 (fi) | ||
| JP2007511504A5 (fi) | ||
| JP2008535903A5 (fi) | ||
| JP2013537203A5 (fi) | ||
| JP2008531574A5 (fi) | ||
| JP2015537017A5 (fi) | ||
| JP2012505872A5 (fi) | ||
| RU2010127786A (ru) | Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение | |
| JP2009503110A5 (fi) | ||
| JP2009539943A5 (fi) | ||
| JP2006509842A5 (fi) | ||
| JP2008544975A5 (fi) | ||
| JP2018525425A5 (fi) |